<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121132">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02056171</url>
  </required_header>
  <id_info>
    <org_study_id>1309014323</org_study_id>
    <nct_id>NCT02056171</nct_id>
  </id_info>
  <brief_title>Efficacy of Quetiapine for Pediatric Delirium</brief_title>
  <official_title>Efficacy of Quetiapine for Pediatric Delirium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many children in the ICU become confused, due to their underlying illness or treatment
      effects. The medical term for this confusion is delirium. In adults, a medication called
      quetiapine has been effective in treating delirium. This is considered an &quot;off label&quot; use as
      the FDA has not approved quetiapine for this indication.

      Pediatricians have been using quetiapine to treat delirium in children as well, but there is
      currently no data proving that it is effective in children. This study is being done to
      determine if quetiapine is effective for the treatment of ICU delirium in children.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to first resolution of delirium</measure>
    <time_frame>Within the first 10 days after study enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total ICU days with delirium</measure>
    <time_frame>Within 30 days after study enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in delirium severity</measure>
    <time_frame>within 10 days of study enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>Quetiapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A randomized group will receive quetiapine as treatment for delirium.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A randomized group will receive placebo, and not quetiapine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine</intervention_name>
    <arm_group_label>Quetiapine</arm_group_label>
    <other_name>Seroquil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Any patient in the PICU aged 1 year to 21 years old who is diagnosed with delirium

        Exclusion Criteria:

          -  Age &lt;1

          -  Richmond Agitation Sedation Scale (RASS) score of -4 or -5 (deeply sedated or
             unarousable).

          -  current treatment for alcohol withdrawal

          -  hepatic encephalopathy

          -  pregnancy

          -  diagnosis of major depressive disorder or bipolar disorder

          -  diagnosis of movement disorder

          -  diagnosis of diabetic ketoacidosis

          -  baseline QTc &gt;500 milliseconds

          -  non-English speaking subjects and/or parent/guardian
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chani Traube, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chani Traube, MD</last_name>
    <phone>212-746-3056</phone>
    <email>chr9008@med.cornell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>NY Prebyterian Hospital/Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chani Traube, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabrielle Silver, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Witcher, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Mendez-Rico, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Joyce, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>February 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>delirium</keyword>
  <keyword>pediatrics</keyword>
  <keyword>critical care</keyword>
  <keyword>quetiapine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Quetiapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
